---
trial_id: 1541
discovery_date: 2022-07-29 15:03:31.671665
date: 2022-07-29 15:03:31.671665
title: "A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long..."
summary: |
  <p>EudraCT Number: 2022-000049-34<br />Sponsor Protocol Number: ACT16753<br />Sponsor Name: Sanofi-aventis recherche & développement<br />Start Date: 2022-07-21<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/ES">ES</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000049-34'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2022-000049-34<br />Sponsor Protocol Number: ACT16753<br />Sponsor Name: Sanofi-aventis recherche & développement<br />Start Date: 2022-07-21<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/ES">ES</a> (Ongoing)</p>